Redevelop novel form of fluticasone (API in $1 billion Flovent) from BID to QD asthma product via 505(b)2 FDA pathway w/ new 20-year IP life
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free